AAAAAA
Results:
1-14
|
Results: 14
Authors:
Saltz, L
Citation: L. Saltz, The role of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer - The Khayat et al article reviewed, ONCOLOGY-NY, 15(4), 2001, pp. 429-430
Authors:
Kemeny, N
Gonen, M
Sullivan, D
Schwartz, L
Benedetti, F
Saltz, L
Stockman, J
Fong, Y
Jarnagin, W
Bertino, J
Tong, W
Paty, P
Citation: N. Kemeny et al., Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer, J CL ONCOL, 19(10), 2001, pp. 2687-2695
Authors:
Grann, A
Feng, C
Wong, D
Saltz, L
Paty, PP
Guillem, JG
Cohen, AM
Minsky, BD
Citation: A. Grann et al., Preoperative combined modality therapy for clinically resectable UT3 rectal adenocarcinoma, INT J RAD O, 49(4), 2001, pp. 987-995
Authors:
Brentjens, R
Saltz, L
Citation: R. Brentjens et L. Saltz, Islet cell tumors of the pancreas - The medical oncologist's perspective, SURG CL NA, 81(3), 2001, pp. 527
Authors:
Nissan, A
Guillem, JG
Paty, PB
Wong, WD
Minsky, B
Saltz, L
Cohen, AM
Citation: A. Nissan et al., Abdominoperineal resection for rectal cancer at a specialty center, DIS COL REC, 44(1), 2001, pp. 27-35
Authors:
Koea, JB
Guillem, JG
Conlon, KC
Minsky, B
Saltz, L
Cohen, A
Citation: Jb. Koea et al., Role of laparoscopy in the initial multimodality management of patients with near-obstructing rectal cancer, J GASTRO S, 4(1), 2000, pp. 105-108
Authors:
Chamberlain, RS
Canes, D
Brown, KT
Saltz, L
Jarnagin, W
Fong, YM
Blumgart, LH
Citation: Rs. Chamberlain et al., Hepatic neuroendocrine metastases: Does intervention alter outcomes?, J AM COLL S, 190(4), 2000, pp. 432-445
Authors:
Saltz, L
Citation: L. Saltz, Irinotecan-based combinations for the adjuvant treatment of stage III colon cancer, ONCOLOGY-NY, 14(12), 2000, pp. 47-50
Authors:
Rosenthal, DI
Haller, DG
Saltz, L
Semple, D
Minsky, BD
Citation: Di. Rosenthal et al., Postoperative radiation therapy for rectal cancer combined with UFT/leucovorin, ONCOLOGY-NY, 14(10), 2000, pp. 59-62
Authors:
Schwartz, GK
Ilson, D
Saltz, L
O'Reilly, E
Tong, W
Maslak, P
Werner, J
Perkins, P
Stoltz, M
Kelsen, D
Citation: Gk. Schwartz et al., Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma, J CL ONCOL, 19(7), 2000, pp. 1985-1992
Authors:
Guillem, JG
Puig-La Calle, J
Akhurst, T
Tickoo, S
Ruo, L
Minsky, BD
Gollub, MJ
Klimstra, DS
Mazumdar, M
Paty, PB
Macapinlac, H
Yeung, H
Saltz, L
Finn, RD
Erdi, Y
Humm, J
Cohen, AM
Larson, S
Citation: Jg. Guillem et al., Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography, DIS COL REC, 43(1), 2000, pp. 18-24
Authors:
Rubin, J
Ajani, J
Schirmer, W
Venook, AP
Bukowski, R
Pommier, R
Saltz, L
Dandona, P
Anthony, L
Citation: J. Rubin et al., Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome, J CL ONCOL, 17(2), 1999, pp. 600-606
Authors:
Ilson, DH
Saltz, L
Enzinger, P
Huang, Y
Kornblith, A
Gollub, M
O'Reilly, E
Schwartz, G
DeGroff, J
Gonzalez, G
Kelsen, DP
Citation: Dh. Ilson et al., Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer, J CL ONCOL, 17(10), 1999, pp. 3270-3275
Authors:
Wagman, R
Minsky, BD
Cohen, AM
Saltz, L
Paty, PB
Guillem, JG
Citation: R. Wagman et al., Conservative management of rectal cancer with local excision and postoperative adjuvant therapy, INT J RAD O, 44(4), 1999, pp. 841-846
Risultati:
1-14
|